Elanco Animal Health Incorporated

Elanco Animal Health Incorporated

ELANยทNYSE

$24.58

+3.9%
HealthcareDrug Manufacturers - Specialty & Generic

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

At a Glance

Live Snapshot
Market Cap$12.28B
EPS-0.4700
P/E Ratio-52.30
Earnings Date08/06/2026
3Y+7.0%
5Y+44.0%
10Y+62.0%
3Y+197.0%
5Y-59.0%
10Y+384.0%
3Y+24.0%
5Y-1466.0%
10Y+259.0%
Elanco Animal Health Incorporated

Elanco Animal Health Incorporated Profit Bridge

ELAN ยท NYSE
Revenue4.71B
Cost of Goods Sold (2.67B)
Gross Profit2.05B
Operating Expenses (1.80B)
Operating Income252.00M
Interest Expense (220.00M)
Other Income/Expense-476.00M
Pretax Income-224.00M
Income Tax (8.00M)
Net Income-232.00M
Net Income
-232.00M

Profitability Analysis

Gross Margin

43.5%

Strong gross margins indicate healthy pricing and efficient production or service delivery.

Operating Margin

5.3%

Acceptable margins but limited operational leverage. Operating expense control is important.

Net Profit Margin

-4.9%

Net losses indicate the company is burning cash. Sustainability depends on path to profitability.

Profitability Insight

Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.

Elanco Animal Health Incorporated Income Statement

ELAN โ€ข NYSE

Elanco Animal Health Incorporated Income StatementDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016Dec 2015
REVENUE
4.7B
4.4B
4.4B
4.4B
4.8B
3.3B
3.1B
3.1B
2.9B
2.9B
2.9B
GROSS PROFIT
(2.7B)
(2.5B)
(2.5B)
(2.4B)
(2.7B)
(2B)
(1.7B)
(1.8B)
(1.7B)
(1.6B)
(1.7B)
2.1B
1.9B
1.9B
2B
2.1B
1.2B
1.4B
1.3B
1.2B
1.3B
1.2B
OPERATING INCOME
(1.8B)
(1.7B)
(1.6B)
(1.6B)
(1.8B)
(1.3B)
(1B)
(981.8M)
(1B)
(1.1B)
(1.2B)
(1.4B)
(1.3B)
(1.3B)
(1.3B)
(1.4B)
(996.6M)
(760.2M)
(735.2M)
(779.8M)
(784.8M)
(916M)
(368M)
(344M)
(327M)
(321M)
(369M)
(327M)
(270.1M)
(246.6M)
(251.7M)
(265.8M)
(291M)
252M
251M
326M
384M
304M
-76.8M
370M
313.8M
142.4M
283.2M
5.4M
PRE-TAX INCOME
(220M)
(339M)
(277M)
(256M)
(264M)
(156M)
(78.9M)
(29.6M)
(0.0)
(0.0)
(0.0)
-175M
-339M
-277M
-256M
-264M
-156M
-78.9M
-29.6M
0.0
0.0
0.0
-476M
237M
-1.5B
-456M
-875M
-595.2M
-291.8M
-199.7M
-375M
-305.6M
-264.9M
-224M
488M
-1.2B
-72M
-571M
-672M
78.2M
114.1M
-232.6M
-22.4M
-259.5M
NET INCOME
(8M)
(150M)
(36M)
(6M)
-88M
-111.9M
(10.3M)
(27.6M)
(78.1M)
(25.5M)
-48.7M
-232M
338M
-1.2B
-78M
-483M
-560.1M
67.9M
86.5M
-310.7M
-47.9M
-210.8M

SEC Filings

ELAN - Filing history and reports

Filing TypeFiling DatePeriod EndingFiscal YearActions
8-K

8-K 2026

N/A

May 27, 2026
May 21, 2026
2026
10-Q

10-Q 2026 Q1

Q1

May 06, 2026
March 31, 2026
2026
8-K

8-K 2026

N/A

May 06, 2026
May 06, 2026
2026
DEF 14A

DEF 14A 2025

N/A

April 08, 2026
December 31, 2025
2025
10-K

10-K 2025 FY

FY

February 24, 2026
December 31, 2025
2025
8-K

8-K 2026

N/A

February 24, 2026
February 24, 2026
2026
8-K

8-K 2026

N/A

January 12, 2026
January 12, 2026
2026
8-K

8-K 2025

N/A

December 09, 2025
December 05, 2025
2025
10-Q

10-Q 2025 Q3

Q3

November 05, 2025
September 30, 2025
2025
8-K

8-K 2025

N/A

November 05, 2025
November 05, 2025
2025
Showing 1 to 10 of 164 filings